MDM2 and MDMX have a p53-independent role in cell-cycle progression in the absence of wild-type p53 Nov. 9, 2021
Studies of KL-11743 detail potential oncolytic activity of glucose transporter inhibitors Nov. 8, 2021
STAR-0215, a potent and long-acting MAb plasma kallikrein inhibitor for the treatment of HAE Nov. 8, 2021
Viking Therapeutics' dual GLP-1/GIP receptor agonists show potential in model of obesity Nov. 8, 2021
RSS